Five-year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: final results from the Phase II L-MIND study

J Düll; P Abrisqueta; M Andre; M Augustin; G Gaidano; EG Barca; W Jurczak; N Kalakonda; AM Liberati; KJ Maddocks; T Menne; Z Nagy; O Tournilhac; A Bakuli; A Amin; K Gurbanov; G Salles

Five-year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: final results from the Phase II L-MIND study

J Düll, P Abrisqueta, M Andre, M Augustin, G Gaidano, EG Barca, W Jurczak, N Kalakonda, AM Liberati, KJ Maddocks, T Menne, Z Nagy, O Tournilhac, A Bakuli, A Amin, K Gurbanov, G Salles

Department of Internal Medicine V, Division of Oncology and Hematology

Research output: Contribution to journal › Abstract (Journal) › peer-review

Original language	English
Pages (from-to)	214
Number of pages	1
Journal	Oncology Research and Treatment
Volume	46
Publication status	Published - 2023

Cite this

Düll, J., Abrisqueta, P., Andre, M., Augustin, M., Gaidano, G., Barca, EG., Jurczak, W., Kalakonda, N., Liberati, AM., Maddocks, KJ., Menne, T., Nagy, Z., Tournilhac, O., Bakuli, A., Amin, A., Gurbanov, K., & Salles, G. (2023). Five-year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: final results from the Phase II L-MIND study. Oncology Research and Treatment, 46, 214.

@article{4bafcff884f242958b8cca81bee72b27,

title = "Five-year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: final results from the Phase II L-MIND study",

author = "J D{\"u}ll and P Abrisqueta and M Andre and M Augustin and G Gaidano and EG Barca and W Jurczak and N Kalakonda and AM Liberati and KJ Maddocks and T Menne and Z Nagy and O Tournilhac and A Bakuli and A Amin and K Gurbanov and G Salles",

note = "Times Cited in Web of Science Core Collection: 0 Total Times Cited: 0 Cited Reference Count: 0",

year = "2023",

language = "English",

volume = "46",

pages = "214",

journal = "Oncology Research and Treatment",

issn = "2296-5270",

publisher = "Karger ",

}

Düll, J, Abrisqueta, P, Andre, M, Augustin, M, Gaidano, G, Barca, EG, Jurczak, W, Kalakonda, N, Liberati, AM, Maddocks, KJ, Menne, T, Nagy, Z, Tournilhac, O, Bakuli, A, Amin, A, Gurbanov, K & Salles, G 2023, 'Five-year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: final results from the Phase II L-MIND study', Oncology Research and Treatment, vol. 46, pp. 214.

TY - JOUR

T1 - Five-year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: final results from the Phase II L-MIND study

AU - Düll, J

AU - Abrisqueta, P

AU - Andre, M

AU - Augustin, M

AU - Gaidano, G

AU - Barca, EG

AU - Jurczak, W

AU - Kalakonda, N

AU - Liberati, AM

AU - Maddocks, KJ

AU - Menne, T

AU - Nagy, Z

AU - Tournilhac, O

AU - Bakuli, A

AU - Amin, A

AU - Gurbanov, K

AU - Salles, G

N1 - Times Cited in Web of Science Core Collection: 0 Total Times Cited: 0 Cited Reference Count: 0

PY - 2023

Y1 - 2023

M3 - Abstract (Journal)

SN - 2296-5270

VL - 46

SP - 214

JO - Oncology Research and Treatment

JF - Oncology Research and Treatment

ER -